Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Biodexa Pharmaceuticals PLC ADR represents shares in a clinical-stage biopharmaceutical company incorporated in England and Wales and headquartered in Cardiff, United Kingdom. The company develops a pipeline of innovative treatments targeting diseases with high unmet medical needs, including familial adenomatous polyposis (FAP), type 1 diabetes, TKI-resistant gastrointestinal stromal tumors (GIST), and primary and metastatic brain cancers. Its lead program, eRapa, is a proprietary oral tablet formulation of rapamycin using nanotechnology and pH-sensitive polymers to enhance bioavailability and consistent pharmacokinetics for FAP, where it is advancing toward a phase 3 registration study known as the Serenta trial. MTX240, licensed from Otsuka, is a next-generation molecular glue for TKI-resistant GIST via selective protein degradation. Tolimidone acts as a selective lyn kinase inhibitor for glycemic control in type 1 diabetes through insulin sensitization. MTX110 delivers panobinostat directly to brain tumors via convection-enhanced delivery, bypassing the blood-brain barrier. Biodexa leverages expertise in formulation science and drug delivery platforms to advance therapies for rare and serious conditions.
£2.92
+£0.42 (+16.80%)
EOD Jun 26, 2026 · Twelve Data
Negative free cash flow of -£6M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£6M
▼ -11.4% YoY
Op. Margin
—
ROIC
-66.58%
▲ +35.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£6M
▲ +51.8% YoY
Op. Cash Flow (TTM)
-£3M
▲ +70.6% YoY
Net Debt
-£8M
Net Cash Position
Cash & Equiv.
£9M
Continue Research
Biodexa Pharmaceuticals PLC ADR (BDRX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Biodexa Pharmaceuticals PLC ADR scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Biodexa Pharmaceuticals PLC ADR scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -66.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BDRX's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.